Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Savitri Krishnamurthy

Showing results (171-180 of 262) with videos related to

Pageof 27
Sort By:
Annals of Surgical Oncology|April 24, 2015
Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?Ashleigh M Francis, Christine E Haugen, Lynn M Grimes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinaseChandra Bartholomeusz, Ana M Gonzalez-Angulo, Anna Kazansky, et al.
Annals of Surgical Oncology|April 8, 2003
Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancerRosa F Hwang, Savitri Krishnamurthy, Kelly K Hunt, et al.
Clinical Breast Cancer|July 31, 2017
Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast CancerSarah M DeSnyder, Elizabeth A Mittendorf, Carissa Le-Petross, et al.
Cancer Research|January 30, 2021
Estrogen Receptor β-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast CancerChristoforos Thomas, Ilias V Karagounis, Ratnesh K Srivastava, et al.
Scientific Reports|November 16, 2021
A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancerMegumi Kai, Angela N Marx, Diane D Liu, et al.
BMC Cancer|May 20, 2020
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBCToshiaki Iwase, Kenichi Harano, Hiroko Masuda, et al.
Cell|September 5, 2025
Coalescing single-cell genomes and transcriptomes to decode breast cancer progressionKaile Wang, Rui Ye, Shanshan Bai, et al.
The Oncologist|February 1, 2020
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without TrastuzumabTakahiro Kogawa, Takeo Fujii, Jimin Wu, et al.
JCO Precision Oncology|October 11, 2024
Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader StudySavitri Krishnamurthy, Stuart J Schnitt, Anne Vincent-Salomon, et al.
Pageof 27

Showing results (171-180 of 262) with videos related to

Sort By:
Pageof 27
Annals of Surgical Oncology|April 24, 2015
Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?Ashleigh M Francis, Christine E Haugen, Lynn M Grimes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinaseChandra Bartholomeusz, Ana M Gonzalez-Angulo, Anna Kazansky, et al.
Annals of Surgical Oncology|April 8, 2003
Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancerRosa F Hwang, Savitri Krishnamurthy, Kelly K Hunt, et al.
Clinical Breast Cancer|July 31, 2017
Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast CancerSarah M DeSnyder, Elizabeth A Mittendorf, Carissa Le-Petross, et al.
Cancer Research|January 30, 2021
Estrogen Receptor β-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast CancerChristoforos Thomas, Ilias V Karagounis, Ratnesh K Srivastava, et al.
Scientific Reports|November 16, 2021
A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancerMegumi Kai, Angela N Marx, Diane D Liu, et al.
BMC Cancer|May 20, 2020
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBCToshiaki Iwase, Kenichi Harano, Hiroko Masuda, et al.
Cell|September 5, 2025
Coalescing single-cell genomes and transcriptomes to decode breast cancer progressionKaile Wang, Rui Ye, Shanshan Bai, et al.
The Oncologist|February 1, 2020
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without TrastuzumabTakahiro Kogawa, Takeo Fujii, Jimin Wu, et al.
JCO Precision Oncology|October 11, 2024
Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader StudySavitri Krishnamurthy, Stuart J Schnitt, Anne Vincent-Salomon, et al.
Pageof 27